1. Lumakras (Sotorasib) - First Approved KRAS Inhibitor Drug
1.1 Market Overview
1.2 Future Opportunity

2. Lumakras - Mechanism of Action

3. Lumakras - Structure, Description & Pharmacokinetics
3.1 Chemistry & Physical Properties
3.2 Pharmacokinetics

4. Role of Lumakras in NSCLC

5. Role in Lumakras in Solid Tumors

6. Lumakras - Commercial Aspects
6.1 Overview & Patent Insight
6.2 Dosage & Price Analysis

7. Lumakras - Supplementary Information
7.1 Adverse Drug Reactions
7.2 Drug Interaction
7.2.1 Effects of Other Drugs on Lumakras
7.2.2 Effects of Lumakras on Other Drugs

8. Lumakras Ongoing Clinical Trials
8.1 Global KRAS Protein Inhibitors Clinical Trials
8.2 Global Lumakras Clinical Trials

9. Clinical Development Trends by Regions
9.1 US
9.2 Rest of World

10. Companies Involved in Development of KRAS Inhibitors
10.1 Amgen
10.2 Boehringer Ingelheim
10.3 Codiak Biosciences
10.4 Cotinga Pharmaceuticals
10.5 Eli Lilly
10.6 Gilead
10.7 Johnson & Johnson
10.8 Mirati Therapeutics
10.9 Merck
10.10 Moderna
10.11 Oblique Therapeutics
10.12 Revolution Medicines
10.13 Silenseed

List of Figures
Figure 1-1: Global - Frequency of KRAS G12C Mutation by Cancer Type (%), 2021 & 2026
Figure 1-2: Global - KRAS Mutation by Type (%), 2020
Figure 1-3: Global - Estimated KRAS Mutated NSCLC Population for KRAS Inhibitors, 2021 & 2026
Figure 1-4: Global - NSCLC Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-5: Global - NSCLC Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-6: Global - NSCLC Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-7: Global - NSCLC Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-8: Global - NSCLC Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-9: Global - Estimated KRAS G12C Mutated Colorectal Cancer Population for KRAS Inhibitors, 2021 & 2026
Figure 1-10: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-11: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Billion), 2021 - 2026
Figure 1-12: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-13: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-14: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026

Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer
Figure 2-2: Targeting Approaches of KRAS Inhibitors
Figure 2-3: Mechanism of Lumakras - Direct Targeting of Mutant KRAS


Figure 3-1: Structure of Lumakras

Figure 4-1: Global - Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020
Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer

Figure 5-1: Global - Frequency of Overall KRAS Mutation & KRAS G12C Mutation (%)

Figure 6-1: Lumakras - FDA Approval & Patent Expiration Year
Figure 6-2: Lumakras - Price for 240 Tablet Supply & Price Per Unit of 120mg Tablet (US$), July'2021
Figure 6-3: Lumakras - Monthly & Annual Treatment Cost (US$), July'2021
Figure 6-4: Lumakras - Recommended Initial & Reduced Dose (mg/day)

Figure 7-1: Lumakras - List of Adverse Events

Figure 8-1: Global - KRAS Protein Inhibitors Clinical Trials by Phase, 2020 -2026
Figure 8-2: Global - KRAS Protein Inhibitors Clinical Trials by Country, 2020 -2026
Figure 8-3: Global - KRAS Protein Inhibitors Clinical Trials by Company, 2020 -2026
Figure 8-4: Global - KRAS Protein Inhibitors Clinical Trials by Indication, 2020 -2026
Figure 8-5: Global - KRAS Protein Inhibitors Clinical Trials by Patient Segment, 2020 -2026
Figure 8-6: Global - Number of KRAS G12C Inhibitors in Clinical Trial by Phase, July 2021
Figure 8-7: Global - KRAS G12C Inhibitors in Clinical Trial by Phase (%), July 2021
Figure 8-8: Codebreak 200 Trial - Study Initiation & Expected Completion Year
Figure 8-9: Codebreak 105 Trial - Study Initiation & Expected Completion Year
Figure 8-10: Codebreak 101 Trial - Study Initiation & Expected Completion Year

Companies Mentioned
. Amgen
. Boehringer Ingelheim
. Codiak Biosciences
. Cotinga Pharmaceuticals
. Eli Lilly
. Gilead
. Johnson & Johnson
. Mirati Therapeutics
. Merck
. Moderna
. Oblique Therapeutics
. Revolution Medicines
. Silenseed
.